A Study to Evaluate Ustekinumab in Patients With Plaque Psoriasis in Asia-Pacific Countries

• Status: Completed
• Trial end date: 2013-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine how patients use ustekinumab (label-recommended or other/missed dose interval) in Asia-Pacific countries.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johnson & Johnson Pte Ltd
• Treatments: Ustekinumab

Criteria

Inclusion Criteria:

• Have a diagnosis of plaque psoriasis, according to the dermatologists' clinical judgment

• Agree to initiate treatment with ustekinumab on the same day as enrollment into the study

• Have not received anti-IL12/23 therapies within 6 months prior to enrollment into the study

Exclusion Criteria:

• Has difficulty understanding questions posed by any of the questionnaires

• Are currently participating in an investigational drug clinical study